Cogent Biosciences (COGT) - רווח נקי למניה (EPS TTM)

Cogent Biosciences profitability is independent of market cycles, relying instead on a strict schedule of scientific research. The rolling annual net income per share visualizes revenue dynamics, where the value -2.49 represents the current figure. Successes with bezuklastinib and FDA approval are driving the stock price higher, although high R&D costs in the absence of revenue create significant cash pressure on capital.

Selecting high-quality issuers is based on analyzing a business's ability to generate real income, where net income per share plays a key role. This rolling net income per share metric measures annual equity income; however, for Cogent Biosciences (COGT), which is currently in the clinical trial stage for oncology, it reflects the capital burn rate prior to FDA approval.